MaxCyte Announces Retirement of Board Member Art Mandell

Core Insights - MaxCyte, Inc. announced the retirement of Art Mandell from its Board of Directors effective December 31, 2024, after serving since 2006, contributing significantly to the company's growth and strategic direction [8][4][9] Company Overview - MaxCyte focuses on cell engineering, providing platform technologies to enhance the discovery, development, and commercialization of next-generation cell therapeutics [8] - The company has developed the ExPERT™ platform, which utilizes Flow Electroporation® technology, aimed at supporting the expanding cell therapy market [8][4] - The ExPERT family includes four instruments (ATx™, STx™, GTx™, VLx™), proprietary processing assemblies, and software protocols, backed by a strong intellectual property portfolio [8] Achievements - Under Mr. Mandell's leadership, MaxCyte achieved key milestones such as its initial public offering on the UK AIM exchange and US Nasdaq listing, the launch of the ExPERT™ platform, and signing 29 Strategic Platform Licenses with biotech companies [4][8] - The company also supported the first FDA-approved CRISPR edited non-viral cell therapy in the industry [4]